| Name | Title | Contact Details |
|---|
At Catalyst OrthoScience, our goal is to develop innovative medical solutions that make orthopedic surgery less invasive and more efficient for both surgeons and patients. Catalyst OrthoScience was founded by a board-certified orthopedic surgeon and is comprised of a team of biomedical industry professionals with more than 100 years of combined medical device experience. The Catalyst CSR Total Shoulder System is the result of the visionary insight of Steven Goldberg, M.D., a fellowship-trained orthopedic surgeon and shoulder specialist, who devised the next generation, higher precision, less-invasive total shoulder solution with a greatly simplified method of implant placement. The key design elements of this new system are 1) to preserve as much of the patient`s bone as possible, 2) to create implants to better mimic the natural elliptical shape of the human shoulder, and 3) to provide a system that greatly improves the consistency and reproducibility of the operation.
Lakeshore Biomaterials Inc is a Birmingham, AL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Daedalus Medical Systems is a Alexandria, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Accutron Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
CVRx® is a private company located in Minneapolis, Minnesota. The company has developed proprietary active implantable technology for the treatment of high blood pressure, also referred to as hypertension, and heart failure. The CVRx senior management and technical team have many years of experience commercializing implantable medical devices. The company is supported by an outstanding board of directors and a world-class scientific advisory board, which includes thought leading physicians and scientists in the field of hypertension and heart failure. CVRx has developed an implantable device that is designed to treat high blood pressure and heart failure. This new device called Barostim neo™ is designed to trigger the body`s own natural blood flow regulation system to treat high blood pressure and heart failure. CVRx has a strong intellectual property foundation, which will protect this unique technology. Barostim neo is CE marked in Europe for the treatment of hypertension patients. It is also CE marked in Europe for the treatment of heart failure. This product is currently under clinical evaluation in the United States and Canada for the treatment of high blood pressure and heart failure.